| Abstract: |
The efficacy of chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is well-established. This study, using the Premier PINC AI Healthcare Database, assessed hospital costs and healthcare resource utilization (HRU) between CAR T-cell therapy and autologous hematopoietic cell transplant (AHCT) for 733 LBCL patients from 01/01/2017-04/30/2021 (166 CAR T and 567 AHCT from 37 US hospital systems. CAR T-cell therapy had higher index costs but lower non-pharmacy costs, shorter hospital stays, lower ICU utilization than AHCT. The CAR T-cell cohort also presented fewer preparatory costs and HRU. At a 180-day follow-up, AHCT had lower hospitalization rates and costs. Overall, despite higher index costs, CAR T-cell therapy has lower non-pharmacy costs and HRU during the index procedure and requires less preparation time with lower preparation HRUs and costs than AHCT. This has important implications for resource management and informed decision-making for stakeholders. © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: |
adult; controlled study; aged; middle aged; major clinical study; multimodality cancer therapy; united states; cancer patient; combined modality therapy; follow up; cohort analysis; hematopoietic stem cell transplantation; retrospective study; health care cost; health care utilization; economics; intensive care unit; hospitalization; chimeric antigen receptor; lymphoma, large b-cell, diffuse; observational study; health care costs; patient attitude; transplantation, autologous; therapy; hospital cost; health care planning; adoptive immunotherapy; immunotherapy, adoptive; hospitalization cost; autologous hematopoietic stem cell transplantation; patient acceptance of health care; costs; health resources; hospital costs; autotransplantation; procedures; diffuse large b cell lymphoma; large b-cell lymphoma; humans; human; male; female; article; healthcare resource utilization; chimeric antigen receptor t-cell immunotherapy; car t-cell therapy; real-world evidence; receptors, chimeric antigen
|
